⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8371655 | 0.79 | CYP2D6 (0.35) | — | |
| SCHEMBL8374845 | 0.76 | KDM4E (0.36) | — | |
| SCHEMBL7819419 | 0.69 | — | — | |
| SCHEMBL1710152 | 0.63 | ALDH1A1 (0.31) | — | |
| SCHEMBL29404629 | 0.58 | — | — | |
| SCHEMBL13510843 | 0.58 | — | — | |
| SCHEMBL10710934 | 0.54 | — | — | |
| SCHEMBL11027486 | 0.54 | CYP3A4 (0.32) | — | |
| SCHEMBL3046515 | 0.53 | FDPS (0.31) | — | |
| SCHEMBL20067782 | 0.53 | POLB (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120141391-A1 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20110085993-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110021632-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110008272-A1 | Use of Creatine or Creatine Compounds for Skin Preservation | AVICENA GROUP, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100329997-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100303840-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | AVICENA GROUP, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100226870-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-20090298943-A1 | Use of creatine analogues and creatine kinase modulators for the prevention and treatment of obesity and its related disorders | AVICENA GROUP, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20080119450-A1 | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | AVICENA GROUP, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20070253944-A1 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-7285573-B2 | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | AVICENA GROUP, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7186754-B2 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-6706764-B2 | TREATMENT OF DIABETIC AND TOXIC NEUROPATHIES, PERIPHERAL NERVOUS SYSTEM DISEASES, ALZHEIMER DISEASE, PARKINSON'S DISEASE, STROKE, HUNTINGTON'S DISEASE, AMYOTROPIC LATERAL SCLEROSIS | AVICENA GROUP, INC. | 2004-03-16 | — | — | US | disclosed |